Recurrent endometrial cancer after surgery alone: Results of salvage radiotherapy

被引:58
作者
Jereczek-Fossa, B
Badzio, A
Jassem, J
机构
[1] European Inst Oncol, Dept Radiotherapy, I-20141 Milan, Italy
[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2000年 / 48卷 / 02期
关键词
endometrial carcinoma; recurrence; radiotherapy; prognostic factors; linear-quadratic model;
D O I
10.1016/S0360-3016(00)00642-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Postoperative irradiation of endometrial cancer patients decreases the risk of local recurrence but is associated with a number of long-term sequelae, In a proportion of patients, no immediate postoperative radiotherapy is applied and this treatment is introduced only at relapse. The aim of our study was to assess the long-term results of salvage radiotherapy in previously nonirradiated endometrial cancer patients who developed local recurrence, and to evaluate the impact of patient- and treatment-related factors on treatment efficacy. Methods and Materials: We performed a detailed retrospective analysis of 73 endometrial cancer patients given radiotherapy for local recurrence after the initial surgery only. The mean age at diagnosis of the recurrence was 63 years (range, 39-78 years), Median time to recurrence was 11 months (range, 1-19 months). All recurrences were staged with the use of Perez modification of the International Federation of Gynecology and Obstetrics (FIGO) staging system for primary vaginal carcinoma. There were five (7%) Stage I patients, 43 (59%) Stage II patients, and 25 (34%) Stage III patients. Forty-four patients (60%) received both external beam irradiation (EBRT) and endovaginal brachytherapy (BRT), 17 (23%) received only BRT, and 12 (17%) received only EBRT, The mean total physical radiation dose was 75.9 Gy (range, 8-130 Gy), and the mean normalized total dose (NTD) calculated on the base of the linear-quadratic model was 86.6 Gy (range, 8.5-171.9 Gy), Median follow-up for alive patients was 8.8 years (range, 3-21 years). The impact of patient-, tumor-, and therapy-related factors on the treatment outcome was evaluated with the use of uni- and multivariate analyses. Results: Three- and 5-year overall survival rates were 33% and 25%, respectively. In the univariate analysis, lower stage of recurrent disease (p < 0.0005), combined EBRT and BRT (p = 0.027), higher total radiation dose (p = 0.031), and higher NTD (p = 0.006) were significantly correlated with better survival. In the multivariate analysis, only stage of recurrent disease (p < 0.005) and high total dose (p = 0.047) were independently correlated with better survival. Lower FIGO stage of recurrence (p = 0.023) and higher total dose (p = 0.005) were also independently correlated with longer time to progression, whereas higher radiotherapy dose was the only factor correlated with better local control (p = 0.029). Conclusions: The efficacy of salvage radiotherapy in endometrial cancer patients with local failure after previous surgery is limited. Factors determining treatment outcome include advancement of the tumor at relapse and radiotherapy dose. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:405 / 413
页数:9
相关论文
共 61 条
[41]   Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration [J].
Morris, M ;
Alvarez, RD ;
Kinney, WK ;
Wilson, TO .
GYNECOLOGIC ONCOLOGY, 1996, 60 (02) :288-291
[42]   RELATIONSHIP BETWEEN SURGICAL PATHOLOGICAL RISK-FACTORS AND OUTCOME IN CLINICAL STAGE-I AND STAGE-II CARCINOMA OF THE ENDOMETRIUM - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
MORROW, CP ;
BUNDY, BN ;
KURMAN, RJ ;
CREASMAN, WT ;
HELLER, P ;
HOMESLEY, HD ;
GRAHAM, JE .
GYNECOLOGIC ONCOLOGY, 1991, 40 (01) :55-65
[43]   COMBINED SURGERY AND RADIATION IN ENDOMETRIAL CARCINOMA - AN ANALYSIS OF PROGNOSTIC FACTORS [J].
NORI, D ;
HILARIS, BS ;
TOME, M ;
LEWIS, JL ;
BIRNBAUM, S ;
FUKS, Z .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (04) :489-497
[44]  
PEREZ CA, 1973, CANCER-AM CANCER SOC, V31, P36, DOI 10.1002/1097-0142(197301)31:1<36::AID-CNCR2820310106>3.0.CO
[45]  
2-6
[46]  
PEREZ CA, 1992, PRINCIPLES PRACTICE, P51
[47]  
PEREZ CA, 1997, PRINCIPLES PRACTICE, P1891
[48]   VAGINAL RECURRENCE OF ADENOCARCINOMA OF THE ENDOMETRIUM [J].
PHILLIPS, GL ;
PREM, KA ;
ADCOCK, LL ;
TWIGGS, LB .
GYNECOLOGIC ONCOLOGY, 1982, 13 (03) :323-328
[49]   Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: A phase II study [J].
Pierga, JY ;
Dieras, V ;
Paraiso, D ;
Dorval, T ;
Palangie, T ;
Beuzeboc, P ;
Jouve, M ;
Scholl, SM ;
GarciaGiralt, E ;
Pouillart, P .
GYNECOLOGIC ONCOLOGY, 1996, 60 (01) :59-63
[50]   Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: A phase II study [J].
Pinelli, DM ;
Fiorica, JV ;
Roberts, WS ;
Hoffman, MS ;
Nicosia, SV ;
Cavanagh, D .
GYNECOLOGIC ONCOLOGY, 1996, 60 (03) :462-467